Bob Wasserman has been following healthcare and biotech stocks for over 30 years, with a bias toward value investing. He has been quoted and appeared in a number of print and media outlets, and his education includes degrees from MIT and the University of Chicago. He currently lives in Florida.
Recent Articles By The Author
5 Ways Allergan Can Keep Up Momentum
Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.
Skin in the Game: This Dermatology Market Stock Is a Good M&A Bet
Oculus Innovative Sciences represents a good buy for value investors or cash-rich companies such as Allergan.
How to Invest in Your Favorite MD
Iora Health just raised $75 million in funding and has 34 clinics in 11 states, including Boston and New York.
Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD
Although many biotechnology stocks have fallen this year due to disappointing clinical trial results, what is the deal with this stock that is down precipitously despite encouraging R&D news?
Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space
Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.
Changes at the Top for Endo Could Benefit Its Smaller Partners
The promotion of Paul Campanelli to CEO indicates a change in the company's focus from acquiring other firms to its roots as a generic pharmaceutical firm.
Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen
What to do with $40 billion? That is the question facing Allergan (AGN). One biotechnology stock which stands out as a potential target for Allergan is Applied Genetic Technologies (AGTC).
2 Big Companies and 1 Small One to Target in the Pharma/Biotech Space
Catalent and West Pharmaceutical Services provide products and services to biotech and pharmaceutical firms. Intellipharmaceutics is a small-cap firm on the rise.
ANI Pharmaceuticals' Varied Offerings, Strategic Acquisitions Make It a Good Play for Investors
The Baudette, Minn.-based company has 79 products generating about $4 billion in sales and a number of other promising therapies in its pipeline.
This Little-Known Orthopedic-Device Stock Is Delivering Huge Returns
Even though it has huge, better-known rivals, Exactech (EXAC) is the best-performing stock in the orthopedic products sector this year.